The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thompi
There is a distinction between 'research' use and 'testing' to identify a cancer and suitable drug treatments..
Too many here are unable to differiante between the two that's a fundamental misunderstanding
If you have any clear facts with links showing that Parsortix is fully FDA approved for testing most if not all cancer groups then I suggest you share the link to the source that clearly states such..
As far as I am aware Parsortix is only FDA approved for testing for breast cancer which accounts for 4% of all cancers..
TG2D, you are talking cr*p. Angle, itself, is using Parsortix for studies in ovarian & prostate cancer and plan to offer LDT’s for them. Two of AGL’s customer’s are using Parsortix in non MBC trials. There are countless independent studies using Parsortix for a whole host of different cancer types. AN has explained, on a number of occasions, how CLIA accredited labs can use Parsortix for different cancers. And yet, you still persist talking rubbish.
If your motive is to annoy people, well congratulations it’s working with me. I don’t like filtering people, because I like to hear different views, but I am going to make an exception with you. You’re binned.
Sandy
Oh dear Parsortix approved only for testing 4% of cancers, FACT!
Any ideas why your myopic view aligns to the lack of Parsortix machine sales now?
When you guys actually understand the industry, what clinical approved lab validation involves in the USA rather than simply copy and pasting the same testing results which reflects 'research' only not FDA approval for Parsortix to be used to test for the remaining 96% of other cancers it is currently NOT FDA approved for!
TG2D, Miavoce has patiently explained how CLIA accredited labs can use Parsortix, as have others on the board. Yet you continue to spread malicious misinformation. If you are genuinely concerned, why don’t you email AN? Please do post his reply on here.
If it helps, here is yet another explanation. It is part of AN’s reply to a question asked in the January Proactive presentation.
“So the the clearance is in metastatic breast, that's what FDA recommended. The credibility and the halo effect works across all the cancers, and you can see that in the peer reviewed publications for different types. And the users, if they're accredited clinical labs, they can adopt our system…..And what we've done, is we've created an identical system to the metastatic breast cancer cleared platform, which we're selling as a research use platform. But it's literally identical with a different label on, so it's up to the user to decide how they use it. If we sell it to them for breast then they can literally just turn the handle, if they're going to do lung etc, they've got to make sure that they are happy with the results under their accreditation.”
My point, TGTD, is that further FDA approval of parsortix is not required for labs to offer parsortix based tests in multiple cancer types (unlike what you were claiming).
You simply can't shirk FDA approval seriously!
And you point is?
Hi TGTD
you were recently stating that FDA approval is needed before labs can use Parsortix for cancer types other than MBC. Here is the definitive answer courtesy of Andrew Newland.
'I can confirm that Parsortix may be used in CLIA laboratories for multiple cancer types as long as each laboratory independently establishes and validates a Parsortix based assay specific for the purpose they require. Each laboratory has to take full responsibility for demonstrating adequate analytical performance and securing certification (through CLIA or equivalent) for their individual assays.'
Did you report the matter to your local MP and how did camping outside Astra Zeneca's head office with a placard saying 'Pls buy AGL Now' go down were they interested?
Pump and Dump!
You were warned the exactvsane as back in January!
And no doubt some investors got burned because of your daft copy and past nonsense ffs!
So it's only down 0.56% in the last 5 days, as you have posted.
Not as bad as it might look today then.
ANGLE plc
LON: AGL
OverviewFinancialsCompare
12.40 GBX −1.35 (9.82%)today
12 Apr, 15:53 BST • Disclaimer
ANGLE plc
LON: AGL
OverviewFinancialsCompare
12.40 GBX -0.07 (-0.56%)past 5 days
12 Apr, 15:53 BST • Disclaimer
Similar the the HER2 one but targeting PD-L1 evaluation........................
That would cover most of the Immunotherapy drugs available that are all over the news.
And the sp is down!
Davey50.
Whoever sold the 450,000 will regret it I think.
The Bioview / Angle partnership to market a system that will enable medics to find out the HER2 status of a persons cancer from a simple standard blood test CANNOT BE IGNORED! This information is key to selecting the patients that the Immunotherapy drug targeting HER2 positive patients will work on! Massive savings finding out which ones it will NOT work on of course....... Just a matter of time before we get the RNS to confirm the product launch, or to confirm the other pharma partner they may do a deal with.......... Massive potential for AGL............... MASSIVE!
All IMHO.
Was wondering why you could buy at 12.4p earlier, cleared a 450k seller at 12.1p now NT to buy at 12.5p
Bar none once launched as far as I am aware. It took 6 years for AGL to get their FDA authorisation............
Two very recent examples involving Astrazeneca where HER2 status is key:-
https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
All IMHOl
Highly likely to be a massive winner once launched. We had an update Monday:
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html
Don't forget Bioview invested £1.2 million of their own cash to develop this which would leverage BOTH Companies FDA accreditation which means the machines are allowed to be used in the USA. The ONLY one ????????????
Immunotherapy targeting a cancers HER2 status is all over the news of late.
Two very recent examples involving Astrazeneca:-
https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
All IMHO.
Highly likely to be a massive winner once launched. We had an update just last Monday:
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html
Don't forget Bioview invested £1.2 million of their own cash to develop this which would leverage BOTH Companies FDA accreditation which maens the machines are allowed to be used in the USA................
All IMHO.
So we lost £21m in 2023 but have made savings that are expected to save £3m. That would give a loss of £18m, but we expect to tripe revenue (recognised) to £6.6m. Ignoring the fact it’s recognised not received that gives a loss of £11.4m from a starting cash point of £15m.
So we better hope the next trading update / results don’t downgrade revenue or the runway will begin to look very short. They’ve also said they expect to break even end of 2025. If we assume (guess) costs stay static at £18m, then we’d need to again treble the revenue going forward.
We need to get a commercial move on.
Any news on the £6m anticipated additional revenues needed to extend the cash run way to Q2 2025 bearing in mind monthly cash burn of over £1.4m, thought not, won't hold my breath here!
Expect more fudging and number games from Newland at the next results and trading sorry meant non trading update or is it funding update, never can tell with Newland!
Streamlining of the Services business outlined below is anticipated to result in c. £0.5 million of non-cash impairments and c. £0.7 million of one-off cash costs in 2023 resulting in an operating loss for the year of c. £21 million, which remains in line with consensus despite the additional charges. The streamlining is expected to deliver cost savings of c. £3 million per annum in 2024 resulting in the extension of the cash runway into Q2 2025.
Streamlining of the Services business outlined below is anticipated to result in c. £0.5 million of non-cash impairments and c. £0.7 million of one-off cash costs in 2023 resulting in an operating loss for the year of c. £21 million, which remains in line with consensus despite the additional charges. The streamlining is expected to deliver cost savings of c. £3 million per annum in 2024 resulting in the extension of the cash runway into Q2 2025.
"Angle Plc Parsortix market. Parsortix machine is FDA appproved for Breast cancer as we know "
And here in lies the dilemma Parsortix is only FDA approved for testing 4% of cancers that is it is only approved for testing breast cancer..
The issue for clinical labs is that Newland is saying its down to them to get FDA accreditation to test for the remaining 96% of cancers.
Well here's the dilemma why should clinical labs take on the suppliers burden and time and cost seeking approval and run the risk of it being rejected....
Equally buying Parsortix risks that clinical labs inadvertently use it to test for non breast cancers and end up heavily find by the FDA or worse still in multi million dollar suits bought by patients whose cancer was misdiagnosed and hence drug treatment.
Meanwhile cash is no doubt down to just £6m to £7m with no sign of that infamous £6m revenues spouted by Newland back in January...finger wagging in the air...this brings funding back firmly into the spot light as cash dwindles from the £22m raised from last years placement on top of the £130m of investors money burnt so far!
Thanks EC.
Bad day for EC share price red ramp fest over!
Bantham
Newland was trying to cover his back.
Imagine a situation a lab buys the Parsortix machine which is only FDA approved for beast cancer testing and a lab clinical technician inadvertently uses the machine to test and send cancer results out to doctor and patients to which Parsortix is not approved to be used to test and diagnose drug treatments....this leads to the risk of misdiagnosis, wrong drugs issued, or the very least a breach of US stringent health regulations leading to multi million dollar fines or at worst multi billion door law suits and associated bad press....ergo no material Parsortix sales to date!